Uniquity Bio is focused on developing innovative therapeutics for immune-mediated diseases, leveraging a strong foundation in immunology and inflammation. Their lead asset, solrikitug, is a monoclonal antibody that targets thymic stromal lymphopoietin (TSLP), a key cytokine involved in the inflammatory response. This technology aims to provide best-in-class efficacy for conditions such as chronic obstructive pulmonary disease (COPD), asthma, and eosinophilic esophagitis (EoE), which currently have limited treatment options. The company is committed to advancing its pipeline through rigorous clinical trials, with solrikitug already in Phase 2 trials for multiple indications.

In addition to solrikitug, Uniquity Bio is exploring bispecific antibody programs that build on the TSLP-targeting approach, indicating a strategic focus on maximizing the therapeutic potential of this cytokine. The company emphasizes a robust manufacturing process to ensure efficient development and rapid progression into late-stage clinical trials. By combining scientific expertise with operational agility, Uniquity Bio aims to deliver transformative solutions for patients suffering from immune-mediated diseases, while also creating value for investors and partners through various collaboration opportunities.

United States

Uniquity Bio is a clinical-stage drug development company dedicated to advancing scientific innovation to deliver novel medicines for patients with immunology and inflammation conditions.

Uniquity Bio

Company Details